<div class="headers"><div>Figure 2. Achievement of sUA <6.0 mg/dl. FEB, febuxostat; ALLO, allopurinol. (a) all patients: a p < 0.001 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in diabetic patients; b p < 0.001 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in non-diabetic patients; c p < 0.050 for comparison between diabetic and non-diabetic subjects receiving ALLO. (b) Patients with mild renal impairment: a p < 0.050 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in diabetic patients; b p < 0.001 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in non-diabetic patients; c 2 patients with mild renal impairment received 200 mg ALLO. (c) Patients with moderate renal impairment: a p < 0.001 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in diabetic patients; b p < 0.050 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in non-diabetic patients; c p < 0.050 for comparison between diabetic and non-diabetic patients receiving FEB 40 mg; d p < 0.050 for comparison between diabetic and non-diabetic subjects receiving FEB 80 mg; e 1 patient with moderate renal impairment received 300 mg ALLO.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Figure 2. Achievement of sUA <6.0 mg/dl. FEB, febuxostat; ALLO, allopurinol. (a) all patients: a p < 0.001 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in diabetic patients; b p < 0.001 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in non-diabetic patients; c p < 0.050 for comparison between diabetic and non-diabetic subjects receiving ALLO. (b) Patients with mild renal impairment: a p < 0.050 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in diabetic patients; b p < 0.001 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in non-diabetic patients; c 2 patients with mild renal impairment received 200 mg ALLO. (c) Patients with moderate renal impairment: a p < 0.001 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in diabetic patients; b p < 0.050 for comparisons between FEB 80 mg and either FEB 40 mg or ALLO in non-diabetic patients; c p < 0.050 for comparison between diabetic and non-diabetic patients receiving FEB 40 mg; d p < 0.050 for comparison between diabetic and non-diabetic subjects receiving FEB 80 mg; e 1 patient with moderate renal impairment received 300 mg ALLO.</p></td>
</tr>
</tbody>
</table>
